- Home
- CYCU vs RVPH Comparison
CYCU vs RVPH Comparison
Compare CYCU & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCU
- RVPH
- Stock Information
- Founded
- CYCU 2017
- RVPH 2006
- Country
- CYCU United States
- RVPH United States
- Employees
- CYCU N/A
- RVPH N/A
- Industry
- CYCU
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- CYCU
- RVPH Health Care
- Exchange
- CYCU Nasdaq
- RVPH Nasdaq
- Market Cap
- CYCU 17.8M
- RVPH 18.1M
- IPO Year
- CYCU N/A
- RVPH N/A
- Fundamental
- Price
- CYCU $2.65
- RVPH $0.56
- Analyst Decision
- CYCU
- RVPH Strong Buy
- Analyst Count
- CYCU 0
- RVPH 6
- Target Price
- CYCU N/A
- RVPH $3.33
- AVG Volume (30 Days)
- CYCU 650.6K
- RVPH 12.6M
- Earning Date
- CYCU 11-13-2025
- RVPH 11-14-2025
- Dividend Yield
- CYCU N/A
- RVPH N/A
- EPS Growth
- CYCU N/A
- RVPH N/A
- EPS
- CYCU N/A
- RVPH N/A
- Revenue
- CYCU $16,285,283.00
- RVPH N/A
- Revenue This Year
- CYCU N/A
- RVPH N/A
- Revenue Next Year
- CYCU N/A
- RVPH N/A
- P/E Ratio
- CYCU N/A
- RVPH N/A
- Revenue Growth
- CYCU N/A
- RVPH N/A
- 52 Week Low
- CYCU $2.79
- RVPH $0.25
- 52 Week High
- CYCU $329.70
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- CYCU 63.06
- RVPH 50.38
- Support Level
- CYCU $3.30
- RVPH $0.53
- Resistance Level
- CYCU $5.05
- RVPH $0.65
- Average True Range (ATR)
- CYCU 0.38
- RVPH 0.07
- MACD
- CYCU 0.15
- RVPH -0.01
- Stochastic Oscillator
- CYCU 50.95
- RVPH 50.36
About CYCU Cycurion Inc. Common Stock
Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.